Patents by Inventor Jami Kern

Jami Kern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE, DERIVATIVES AND TABLETS THEREOF, AND THEIR PHARMACOKINETICS
    Publication number: 20260240778
    Abstract: Provided herein are pharmaceutical composition(s) in the form an oral tablet and methods of making comprising a tablet comprising N-acetylcysteine amide (NACA) and one or more NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers, wherein greater than 90, 91, 92, 93, 94, 95, 96, 97, 98, or 100% of the tablets meet at least one of assay, target weight, thickness range, content uniformity, or chiral purity specification.
    Type: Application
    Filed: April 8, 2026
    Publication date: August 20, 2026
    Inventors: G. Michael Wall, Jami Kern, Roshan Fernando
  • Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide
    Patent number: 12667548
    Abstract: Provided herein are methods for the treatment of retinitis pigmentosa in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA).
    Type: Grant
    Filed: September 24, 2025
    Date of Patent: June 30, 2026
    Assignee: Nacuity Pharmaceuticals, Inc.
    Inventors: Jami Kern, G. Michael Wall
  • N-Acetylcysteine Amide Tablets Inhibit Reduction in Vision in Patients with Usher Syndrome Associated Retinitis Pigmentosa
    Publication number: 20260083688
    Abstract: Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg/day.
    Type: Application
    Filed: September 24, 2025
    Publication date: March 26, 2026
    Inventors: G. Michael Wall, Jami Kern
  • TREATMENT OF RETINITIS PIGMENTOSA AND RETINITIS PIGMENTOSA ASSOCIATED WITH USHER SYNDROME WITH N-ACETYLCYSTEINE AMIDE
    Publication number: 20260014102
    Abstract: Provided herein are methods for the treatment of retinitis pigmentosa in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA).
    Type: Application
    Filed: September 24, 2025
    Publication date: January 15, 2026
    Inventors: Jami Kern, G. Michael Wall